SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2022 Sep 1

PMID 36048774

Authors

Alexander C Keyel

Alexis Russell

Jonathan Plitnick

Jemma V Rowlands

Daryl M Lamson

Eli Rosenberg

Kirsten St George

Affiliations

Soon will be listed here.

Abstract

Recently emerged SARS-CoV-2 variants have greater potential than earlier variants to cause vaccine breakthrough infections. During emergence of the Delta and Omicron variants, a matched case-control analysis used a viral genomic sequence dataset linked with demographic and vaccination information from New York, USA, to examine associations between virus lineage and patient vaccination status, patient age, vaccine type, and time since vaccination. Case-patients were persons infected with the emerging virus lineage, and controls were persons infected with any other virus lineage. Infections in fully vaccinated and boosted persons were significantly associated with the Omicron lineage. Odds of infection with Omicron relative to Delta generally decreased with increasing patient age. A similar pattern was observed with vaccination status during Delta emergence but was not significant. Vaccines offered less protection against Omicron, thereby increasing the number of potential hosts for emerging variants.

Citing Articles

High-frequency PCR-testing as a powerful approach for SARS-CoV-2 surveillance in the field of critical infrastructure: A longitudinal, retrospective study in a German tertiary care hospital.

Fischer B, Farr M, Gummert J, Knabbe C, Vollmer T PLoS One. 2025; 20(2):e0317009.

PMID: 39913462 PMC: 11801583. DOI: 10.1371/journal.pone.0317009.

The Scabbard of Excalibur: An Allegory on the Role of an Efficient and Effective Healthcare System under Universal Health Coverage during the Pandemic Response.

Noda H Healthcare (Basel). 2024; 12(10).

PMID: 38786389 PMC: 11120855. DOI: 10.3390/healthcare12100979.

Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon.

Nour D, Ismail M, Osman M, Rafei R, Kasir D, Dabboussi F PLoS One. 2024; 19(5):e0302579.

PMID: 38722969 PMC: 11081361. DOI: 10.1371/journal.pone.0302579.

Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants.

Liu R, Natekar J, Kim K, Pathak H, Bhatnagar N, Raha J Vaccines (Basel). 2024; 12(4.

PMID: 38675744 PMC: 11053539. DOI: 10.3390/vaccines12040362.

Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2.

Lee D, Jung H, Park D, Bang J, Cheong D, Jang J Nat Commun. 2024; 15(1):2108.

PMID: 38453923 PMC: 10920794. DOI: 10.1038/s41467-024-46296-7.

References

Chen J, Wang R, Gilby N, Wei G . Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022; 62(2):412-422. PMC: 8751645. DOI: 10.1021/acs.jcim.1c01451. View

Plitnick J, Griesemer S, Lasek-Nesselquist E, Singh N, Lamson D, St George K . Whole-Genome Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq Panel and Comparison with the Illumina MiSeq ARTIC Protocol. J Clin Microbiol. 2021; 59(12):e0064921. PMC: 8601232. DOI: 10.1128/JCM.00649-21. View

Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M . Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022; 27(9). PMC: 8895467. DOI: 10.2807/1560-7917.ES.2022.27.9.2200121. View

Li B, Deng A, Li K, Hu Y, Li Z, Shi Y . Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nat Commun. 2022; 13(1):460. PMC: 8786931. DOI: 10.1038/s41467-022-28089-y. View

Bashor L, Gagne R, Bosco-Lauth A, Bowen R, Stenglein M, VandeWoude S . SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection. Proc Natl Acad Sci U S A. 2021; 118(44). PMC: 8612357. DOI: 10.1073/pnas.2105253118. View

Atmar R, Lyke K, Deming M, Jackson L, Branche A, El Sahly H . Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022; 386(11):1046-1057. PMC: 8820244. DOI: 10.1056/NEJMoa2116414. View

Yamey G, Walensky R . Covid-19: re-opening universities is high risk. BMJ. 2020; 370:m3365. DOI: 10.1136/bmj.m3365. View

Nyberg T, Ferguson N, Nash S, Webster H, Flaxman S, Andrews N . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303-1312. PMC: 8926413. DOI: 10.1016/S0140-6736(22)00462-7. View

Liu L, Iketani S, Guo Y, Chan J, Wang M, Liu L . Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022; 602(7898):676-681. DOI: 10.1038/s41586-021-04388-0. View

10.

Rosenberg E, Dorabawila V, Easton D, Bauer U, Kumar J, Hoen R . Covid-19 Vaccine Effectiveness in New York State. N Engl J Med. 2021; 386(2):116-127. PMC: 8693697. DOI: 10.1056/NEJMoa2116063. View

11.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

12.

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

13.

Hoffmann M, Kruger N, Schulz S, Cossmann A, Rocha C, Kempf A . The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022; 185(3):447-456.e11. PMC: 8702401. DOI: 10.1016/j.cell.2021.12.032. View

14.

Hale V, Dennis P, McBride D, Nolting J, Madden C, Huey D . SARS-CoV-2 infection in free-ranging white-tailed deer. Nature. 2021; 602(7897):481-486. PMC: 8857059. DOI: 10.1038/s41586-021-04353-x. View

15.

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

16.

Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M . Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021; 27(8):1379-1384. PMC: 8363499. DOI: 10.1038/s41591-021-01413-7. View

17.

Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F . Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med. 2022; 3(5):325-334.e4. PMC: 8983481. DOI: 10.1016/j.medj.2022.03.010. View

18.

Meredith G, Diel D, Frazier P, Henderson S, Koretzky G, Wan J . Routine Surveillance and Vaccination on a University Campus During the Spread of the SARS-CoV-2 Omicron Variant. JAMA Netw Open. 2022; 5(5):e2212906. PMC: 9118068. DOI: 10.1001/jamanetworkopen.2022.12906. View

19.

Demidenko E . Sample size determination for logistic regression revisited. Stat Med. 2006; 26(18):3385-97. DOI: 10.1002/sim.2771. View

20.

Borges V, Isidro J, Cunha M, Cochicho D, Martins L, Banha L . Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. mSphere. 2021; 6(4):e0024421. PMC: 8386466. DOI: 10.1128/mSphere.00244-21. View